Complete UK Conversion Chart - Both Treatments Available
Understanding Wegovy to Mounjaro Conversion Chart Differences
When reviewing a Wegovy to Mounjaro conversion chart, it's crucial to understand these aren't directly interchangeable medications with simple dose-equivalent swaps. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors simultaneously. This fundamental mechanism difference means any Wegovy to Mounjaro conversion chart should focus on therapeutic equivalence rather than milligram-to-milligram comparison.
The most significant advantage for UK patients is immediate availability of both treatments through EverydayMeds. Unlike historical supply shortages that affected Wegovy access, our reliable supply chain from Novo Nordisk ensures all five Wegovy doses remain consistently in stock. Mounjaro availability has also stabilised, meaning patients can choose between treatments based on clinical suitability rather than supply constraints affecting their weight management timeline.
Wegovy to Mounjaro Conversion Chart Pricing Structure
Our transparent pricing makes any Wegovy to Mounjaro conversion chart comparison straightforward for UK patients. Wegovy starts at £79.99 for the 0.25mg starter dose, escalating through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 to reach these final prices. Our bundle options provide treatment continuity—the Intro Trio covering your first 12 weeks costs £299.99.
When comparing costs in your Wegovy to Mounjaro conversion chart evaluation, consider the complete treatment pathway rather than individual pen prices. Wegovy's five-dose escalation requires careful planning, whilst Mounjaro follows a four-step schedule with different pricing. Both treatments require the same reduced-calorie diet and increased physical activity commitment, making the choice about mechanism preference and individual response rather than cost alone.
Clinical Evidence Supporting Wegovy to Mounjaro Conversion Chart Decisions
The STEP trial programme provides robust evidence for Wegovy's efficacy, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). STEP 5 confirmed sustained weight management with approximately 15.2% maintained loss over two years. The SELECT cardiovascular outcomes study showed a 20% reduction in major adverse cardiovascular events.
Mounjaro's SURMOUNT trials demonstrated comparable efficacy through its dual-agonist mechanism, though direct head-to-head comparison isn't appropriate due to different trial designs and patient populations. Any comprehensive Wegovy to Mounjaro conversion chart should present both evidence bases separately, allowing prescribers and patients to evaluate which mechanism may suit individual clinical circumstances best.
How Wegovy Works in Your Conversion Chart Analysis
Understanding Wegovy's mechanism helps inform any Wegovy to Mounjaro conversion chart decision-making process. Semaglutide mimics the GLP-1 hormone naturally produced in your intestines after eating, binding to GLP-1 receptors in your brain's appetite control centres. This binding action reduces appetite signals whilst promoting satiety—the feeling of fullness after smaller meals. The medication may also reduce food cravings by modulating reward pathways associated with eating behaviour. Unlike rapid-acting appetite suppressants, Wegovy works gradually as doses escalate over 16 weeks, allowing your body to adjust to reduced caloric intake whilst maintaining nutritional adequacy.
Streamlined Ordering Process for Both Conversion Chart Options
Whether your Wegovy to Mounjaro conversion chart research leads you to choose Wegovy or switch to Mounjaro, our ordering process remains identical for both prescription-only medicines. Complete our 3-minute online clinical assessment covering your weight management history, current medications, and treatment goals. Our prescribers review applications within three working days (24 hours with express service), ensuring thorough evaluation of your suitability for either treatment. Once approved, both medications ship via next-day cold-chain delivery maintaining the 2-8°C temperature requirements throughout transit. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance for both treatment options.
Storage Considerations in Your Wegovy to Mounjaro Conversion Chart
Storage requirements represent a practical difference worth noting in any Wegovy to Mounjaro conversion chart comparison. Both medications require refrigeration at 2-8°C before first use, but Wegovy offers superior room temperature stability—six weeks below 30°C once removed from the fridge compared to Mounjaro's 21-day limit. This advantage particularly benefits frequent travellers or those with limited refrigeration access during holidays. Both use pre-filled injection pens (Wegovy's FlexTouch system) with identical once-weekly administration, making the transition between treatments straightforward from a practical perspective.
Wegovy to Mounjaro Conversion Chart Supply Chain Reliability
Historical Wegovy shortages made conversion chart discussions academic when the medication simply wasn't available. Our partnership with Novo Nordisk now ensures consistent UK supply across all five doses, eliminating the supply lottery that previously affected patient care. This reliability means conversion chart decisions can focus on clinical appropriateness rather than availability constraints. Stock levels are monitored daily with automatic reordering preventing gaps in supply chains.
For patients considering conversion timing, we maintain buffer stock levels allowing immediate dispensing without treatment interruptions. Whether escalating through Wegovy's dose schedule or transitioning from Mounjaro, continuous treatment availability supports optimal weight management outcomes. Both medications are available for immediate dispatch, removing supply chain uncertainty from your treatment planning process.
Making Your Wegovy to Mounjaro Conversion Chart Decision
Your final Wegovy to Mounjaro conversion chart decision should balance mechanism preferences, practical considerations, and individual response patterns with prescriber guidance. Both treatments are available from £79.99 through our GPhC-registered service (#9012878), with identical assessment and delivery processes ensuring smooth treatment initiation. Apply code FIRST40 for new customer pricing or DOSE25 for returning patients at checkout to access our competitive rates. Our clinical team provides ongoing support throughout your weight management journey, whether you choose Wegovy's selective GLP-1 targeting or Mounjaro's dual-receptor approach. Order today through https://everydaymeds.co.uk/collections/wegovy to begin your clinically-supervised weight management programme with next-day delivery across the UK.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
